Cefotaxime: Single agent therapy for infections in cancer patients with adequate granulocyte counts

Kenneth Rolston, Ricardo Bolivar, Victor Fainstein, Paula Jones, Linda Elting, Gerald P. Bodey

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Seventy-eight infectious episodes in 75 cancer patients with adequate granulocyte counts were treated with cefotaxime. Sixty-six episodes were evaluable. The overall cure rate was 77% (51/66). The response rate in 46 episodes where an organism was identified was 72% (33/46). Gram-positive and Gram-negative infections responded equally with rates of 81% and 80%, respectively. Pneumonia, septicaemia and urinary tract infections occurred most frequently and had response rates of 62% (18/29), 90% (9/10) and 91% (10/11), respectively. Polymicrobial infections were associated with a poor response - 40% (4/10). No serious adverse effects occurred. Cefotaxime as a single agent was effective therapy for most Gram-positive and Gram-negative infections in cancer patients with adequate granulocyte counts. Polymicrobial infections and Gram-negative pneumonias might require additional agents.

Original languageEnglish (US)
Pages (from-to)91-96
Number of pages6
JournalJournal of Antimicrobial Chemotherapy
Volume15
Issue number1
DOIs
StatePublished - Jan 1985

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Cefotaxime: Single agent therapy for infections in cancer patients with adequate granulocyte counts'. Together they form a unique fingerprint.

Cite this